Investing.com··Nathan ReiffBig Pharma Faces $175B Patent Cliff: How Biotech ETFs Can Help Investors Navigate the Shift
Major pharma faces $175B in patent expirations over six years, sparking M&A activity. Biotech ETFs $XBI and $IBB offer investors exposure to consolidation and sector volatility.
PFENVOXBIIBBinvestment opportunitypatent cliff